Global Botulinum Toxin Market to surpass USD 8.5 Bn by 2025

January 23, 2020


According to the research report titled ‘Botulinum Toxin Market Size By Product (Botulinum Toxin A, Botulinum Toxin B), By Application (Medical, Aesthetic), By Gender (Female, Male), By Age Group (13-19, 20-29, 30-39, 40-54, 55 and Above), By End-use (Hospitals, Dermatology Clinics, Spas & Cosmetic Centers), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Turkey, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, Egypt, Iran), Application Potential, Competitive Market Share & Forecast, 2019 – 2025’, available with Market Study Report LLC, the global botulinum toxin market is expected to cross USD 8.5 billion by the year 2025.
 

According to the report, high occurrence rate of spasticity and cervical dystonia and rising prevalence of chronic migraines are major factors driving botulinum toxin market growth. The growing inclination towards aesthetics and rising adoption of minimally invasive procedures are further aiding the market expansion.
 

Side effects associated with botulinum toxin procedures such as shortness of breath, nausea, back & neck pain, allergic reactions, and rash may hinder the market. Additionally, high costs of aesthetic procedures coupled with unfavorable reimbursement policies may inhibit the botulinum toxin market growth.
 

As per product type, the report cites that botulinum toxin A market segment accounted for USD 3,323.6 million in the year 2018 and is expected to register continuous growth during the estimated timeframe. Rising number of FDA approvals along with growing demand for botulinum toxin A based products are facilitating the business scenario.
 

Based on the application spectrum, the medical botulinum toxin market segment held 57.3% share in the year 2018. High occurrence of migraine, rising frequency of cervical dystonia, and spasticity, and increasing awareness pertaining to medical applications of botulinum toxin A are stimulating the industry outlook.
 

In terms of gender, male segment is presumed to expand with a CAGR of 10.4 % during the period of 2019-2025. Growing inclination towards looking young coupled with increasing utilization of minimally invasive procedures are fueling the segmental growth.
 

Speaking of age groups, 40-54 age group segment was worth USD 2,649.6 million in the year 2018. Increasing awareness pertaining to availability of aesthetic procedures along with rising per capita income are boosting the growth of the segment.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2100696/
 

Citing end-use landscape, spas & cosmetic centers segment is estimated to grow with a CAGR of 9.5% between 2019 and 2025. Rising number of spas and cosmetic centers coupled with availability of high quality medical facilities will favor the industry landscape.
 

As per the regional analysis, the report states that U.S. botulinum toxin industry was worth USD 3,349.7 million in 2018. High occurrence rate of medical conditions such as chronic migraine, severe axillary hyperhidrosis, and cervical dystonia are contributing towards the popularity of botulinum toxin products across the country. High presence of key industry players is also aiding the market expansion. On the other hand, Brazil botulinum toxin industry is presumed to expand with 10.7 % CAGR through 2025.
 

The prominent companies operating in the botulinum toxin market are Revance Therapeutics Inc., Merz Pharma, Medytox Inc., Ipsen, Hugh Source International Ltd., Gladerma S.A., Eisai Co. Ltd. and Allergan.


Frequently Asked Questions (FAQ) :

According to the report, high occurrence rate of spasticity and cervical dystonia and rising prevalence of chronic migraines are major factors driving botulinum toxin market growth. The growing inclination towards aesthetics and rising adoption of minimally invasive procedures are further aiding the market expansion.
The report cites that botulinum toxin A market segment accounted for USD 3,323.6 million in the year 2018 and is expected to register continuous growth during the estimated timeframe. Rising number of FDA approvals along with growing demand for botulinum toxin A based products are facilitating the business scenario.
The report states that U.S. botulinum toxin industry was worth USD 3,349.7 million in 2018. High occurrence rate of medical conditions such as chronic migraine, severe axillary hyperhidrosis and cervical dystonia are contributing towards the popularity of botulinum toxin products across the country. High presence of key industry players is also aiding the market expansion. On the other hand, Brazil botulinum toxin industry is presumed to expand with 10.7 % CAGR through 2025.
The prominent companies operating in the botulinum toxin market are Revance Therapeutics Inc., Merz Pharma, Medytox Inc., Ipsen, Hugh Source International Ltd., Gladerma S.A., Eisai Co. Ltd., and Allergan.